277

IMSUT Hospital

Department of Urology
泌尿器科Professor
Haruki Kume, M.D., Ph.D.
Project Senior Assistant Professor Sayuri Takahashi, M.D., Ph.D.
Project Assistant Professor
Mariko Tabata, M.D.

教 授
特任講師
特任助教

博士（医学）
博士（医学）

久高田米橋畑

春 喜
さゆり
真梨子

Our department of Urology was established in ISMUT hospital on July 1st, 2020 toimprove the occupancy rate by introducing advanced medical treatments such as
robotic surgery. We successfully performed 842 cases of urological surgery
including 140 cases of robotic surgery, which resulted in increase of the revenue.
Further, we have been engaged in basic research on castration resistant prostatecancer to discover novel drugs by the method of molecular and cell biology.

1.  Basic research
The WNT signaling pathways (canonical andnon-canonical) regulate prostate cancer progression,
but the precise mechanism by which this regulation
occurs has yet to be established. We investigated expression levels of WNTs in prostate cancer tissues andfound that WNT5A is expressed at higher levels incancer cells and in the stroma of non-cancerous regions than in the epithelium in prostate of cancer inpatient samples. Prostate stroma-derived WPMY1cells also highly express WNT5A. WNT5A knockdown in WPMY1 cells (WPMY1-shW5A) results in a
reduction of cancer related genes, EMT-related genes,
and several cytokines by microarray analysis. WNT5A expression is directly regulated by ligand inducible androgen receptor (AR) bound to the WNT5Apromoter. Receptor tyrosine kinase-like orphan receptor 1 (ROR1), one of WNT5A receptors is highly
expressed in samples from prostate cancer patientsand in prostate cancer cell lines. ROR1 knockdown in
PC3 cells (PC3-shRO1) abrogated WNT5A-induced
cell proliferation. These results show that WNT5A instroma cells regulates prostate cancer proliferationand invasion, at least in part, through the ROR1 sign-

aling pathway. Our results suggest that cell-to-cellcommunication between stromal cells and prostatecancer cells enhances prostate cancer progression andROR1 may be a novel therapeutic target for the disease.
2.  Clinic
Since we established the department of Urology inIMSUT Hospital in July,2020, the number of patientshas been increased by introduced from urologicalclinics, hospitals, and other departments of our hospital. Totally 1,680 patients visited our department in
2023 for the purpose of thorough examinations fordiagnosis or surgical treatments.
We totally performed 292 surgical operations in
2023: 43 cases of Robotic-assisted prostatectomy, 10
Robotic-assisted partial nephrectomy, one Laparoscopic nephroureterectomy, three Radical cystectomy
with ileal conduit urinary diversion, 16 open surgery,
28 Trans-urethral resection of bladder tumor, eightTrans-urethral resection of prostate, 14 Trans-urethral
lithotripsy, 23 Ureteroscopy, 41 Ureteral stenting, andfive Botox injection for overactive bladder278Publications
1.		Takahashi S,* Takada I, Hashimoto K, Yokoyama
A, Nakagawa T, Makishima M, Kume H. ESS2controls prostate cancer progression through recruitment of chromodomain helicase DNA binding protein 1. Sci Rep.2023;13(1):12355.
2.		Takahashi S*, Takada I. Recent advances in prostate cancer: WNT signaling, chromatin regulationand transcriptional coregulators. Asian J Androl.2023;25(2):158-165.
3.		Takahashi S*. Carrent Trend of CAR-T Cell Therapy for Metastatic Castration-Resistant ProstateCancer. Jpn J Cancer Chemother.2023;50(10):1038-1042.
4.		Kawai T, Taguchi S, Nozaki K, Kimura N, Oshina
T, Iwaki T, Matsui H, Niimi A, Kamei J, Akiyama
Y, Yamada Y, Sato Y, Yamada D, Kaneko T, Sawayanagi S, Nakayama H, Minamimoto R,Yamashita H, Miyazaki H, Fujimura T, Nakagawa
T, Kume H. Prostate-specific antigen doublingtime predicts the efficacy of site-directed therapy
for oligoprogressive castration-resistant prostatecancer. Prostate Int. 2023.11(4):239-246.
5.		Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko
T, Kamei J, Obinata D, Yamaguchi K, Kakutani S,Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada
Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H,Fujimura T, Fukuhara H, Nakagawa T, Takahashi
S, Kume H. Enfortumab vedotin versus platinum
rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter
propensity score-matched study. Int J Urol. 2023.
30(12):1180-1186.
6.		Hoshina H, Taguchi S, Suyama H, Kishitani K,Akiyama Y, Yamada Y, Sato Y, Yamada D, Akiba
N, Kumasawa K, Mori-Uchino M, Osuga Y, Kume
H. Surgical resection of retinoblastoma-associatedbladder leiomyosarcoma during pregnancy: acase report. BMC Urol. 2023. 23(1):125.
7.		Taguchi S, Onozawa M, Hinotsu S, Kawai T, Mitomi T, Uno S, Kume H. A multicenter, retrospective
observational study investigating baseline characteristics and clinical outcomes in patients withhormone-sensitive prostate cancer treated withprimary androgen deprivation therapy. Jpn J ClinOncol. 2023.53(10):957-965.
8.		Tabata M, Sato Y, Kogure Y, McClure MB, Oshikawa-Kumade Y, Saito Y, Shingaki S, Ito Y, Yuasa M,Koya J, Yoshida K, Kohno T, Miyama Y, MorikawaT, Chiba K, Okada A, Ogawa S, Ushiku T, Shiraishi Y, Kume H, Kataoka K. Inter- and intra-tumor
heterogeneity of genetic and immune profiles ininherited renal cell carcinoma. Cell Rep. 2023.
42(7):112736.
9.		Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura
Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D,
Yamaguchi K, Kakutani S, Kanazawa K, Sugihara
Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y,Yamada D, Enomoto Y, Nishimatsu H, Fujimura T,
Fukuhara H, Nakagawa T, Takahashi S, Kume H.
Validation of a drug-based score in advanced
urothelial carcinoma treated with pembrolizumab. Immunotherapy. 2023. 15(11):827-837.
10.	Kamei J, Sugihara T, Yasunaga H, Matsui H, Sasabuchi Y, Fujimura T, Homma Y, Kume H. Impactof early ureteral drainage on mortality in obstructive pyelonephritis with urolithiasis: an analysisof the Japanese National Database. World J Urol.
2023. 41(5):1365-1371.
11.	Nakamura M, Suzuki M, Izumi T, Tsuru I, Muraki
Y, Kume H. Trends in surgical treatment for prostate cancer: Analysis of National Database Open
Data in Japan. Glob Health Med. 2023.5(1):62-63.
12.	Hakozaki Y, Yamada Y, Takeshima Y, Taguchi S,Kawai T, Nakamura M, Iwaki T, Teshima T,Kinoshita Y, Akiyama Y, Sato Y, Yamada D, Suzuki M, Kume H. Low hemoglobin and PSA kinetics are prognostic factors of overall survival inmetastatic castration-resistant prostate cancer patients. Sci Rep. 2023.13(1):2672.
13.	Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Taguchi S, Tabata M, Kaneko T, Ishikawa A, Miyazaki H, Kondo Y, Matsumoto A, Naito A, Hikatsu M,Fujii Y, Akiyama Y, Yamada Y, Sato Y, Nomiya A,Yamada D, Murata T, Suzuki M, Enomoto Y,
Nishimatsu H, Takeuchi T, Tanaka Y, Kume H.
Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study. World JUrol. 2023.41(3):767-776.
14.	Kitamura T, Suzuki M, Shigehara K, Fukuda K,
Matsuyama T, Kume H. Prevalence of Human
Papillomavirus Types 16/18 and Effect of Vaccination among Japanese Female General Citizens inthe Vaccine Crisis Era. Viruses. 2023.15(1):159.